Tag: hotly
Intercept’s hotly anticipated NASH drug has to wait for its FDA...
Intercept Pharmaceuticals and its closely watched nonalcoholic steatohepatitis (NASH) candidate have hit another snag, this one courtesy of the coronavirus pandemic.
The FDA has put...
